Glakolens, an Istanbul, Turkey-based developer of contact lens based biosensor technologies, raised €465k in seed funding.
ACT Venture Partners made the investment.
The company will use the funds to focus on further refining, testing and then certifying the technology.
Founded by the members of a research group at Boğaziçi University and led by Prof. Günhan Dündar, Dr. Arda Deniz Yalçınkaya and Dr. Hamdi Torun, Glakolens is advancing a novel non-invasive continuous intra-ocular pressure (IOP) diagnostics and monitoring device based on proprietary technology licensed from Boğaziçi University. The company’s strategy is to focus on introducing a product to address specific needs in ophthalmology where there is need for viable products.
The IOP sensor developed by Glakolens is based on a novel non-invasive approach to very accurately diagnose and passively monitor fluctuations in IOP by measuring certain properties of the eye. The data is collected wirelessly over a period without going to the hospital and further processed using various protocols to offer insights.
FinSMEs
25/05/2017